SNCE SCIENCE 37 HLDGS INC

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites

RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

Leveraging its proprietary Metasite™ and Patient Recruitment solutions, Science 37 contributed 28% of all randomized study participants over a 15-month enrollment window. Science 37 averaged 44 patients enrolled per month, while each of the 55 brick-and-mortar sites supporting the trial enrolled an average of two participants per month. Science 37 delivered an enrollment velocity 22x greater than study sites in the trial and reduced the study’s overall time-to-target enrollment.

“When a study sponsor entrusts us to fully accelerate its clinical research, our role becomes twofold,” said Dr. Lianne Marks, Medical Director and Primary Investigator at Science 37. “The first is to improve upon the traditional patient recruitment model using the built-in outreach, screening, and medical consent advantages of our recruitment solution. The second is to further enhance study conduct through our Metasite by expanding participant access to the 90+ percent patient population that is unreachable in brick-and-mortar research,” she added.

Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated research offering. For more information, please visit

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit , or email .

To view studies that Science 37 is actively recruiting for, please visit .

Media Inquiries



Science 37

 



EN
02/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Majo...

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance Science 37’s Virtual Site Model for Clinical Research Impresses in First-of-its-Kind FDA Inspection RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation. The nearly two-week review included, but was not limited to, the Science 37 Metasite™ model and internal processes, technology utilized to support each trial, data integrity, efficacy...

 PRESS RELEASE

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficien...

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation” Science 37’s Patient Recruitment Recognized in Prestigious International Annual Awards Program for Standout Digital Health & Medical Technology Products and Companies RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- , today announced its selection as winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program. , an independent market intelligence organization, recognized Science 37 for its transformative solution to clinical research patient r...

 PRESS RELEASE

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in ...

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial. Leveraging its proprietary Metasite™ and Pat...

 PRESS RELEASE

Science 37 Provides Fully Consented Patients to Sites to Supplement En...

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burden RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., the clinical research industry’s leading MetasiteTM, today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented. While traditional central patient recruitment campaigns have prove...

 PRESS RELEASE

Science 37 to be Acquired by eMed, Expanding Access to Patients and Ac...

Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment Science 37 stockholders to receive $5.75 per share in cash RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today announced that it has entered into a definitive merger agreement to be acquired by eMed, LLC (“eMed”), the leader in on-demand virtual care and treatment for consumers. With the most authoritative in-home testing and treatment solution available...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch